Actavis plc, a leading global specialty pharmaceutical company, and Medicines360, a nonprofit women's health pharmaceutical company, today announced the approval of LILETTA (levonorgestrel-releasing intrauterine system) by the U.S. Food and Drug Administration for use by women to prevent pregnancy for up to three years. [More]

ABIVAX, a clinical stage biotech company developing and commercialising anti-viral compounds and human vaccines, today announced that it has dosed in New Zealand the first patient in a Phase IIb/III clinical trial of ABX203 which is taking place in several countries of the Asia-Pacific region. [More]

Women going through menopause often struggle with weight gain that results when their estrogen levels drop, and many turn to weight-loss supplements to help them shed those extra pounds. But those supplements may cause an accumulation of fat in the liver and a potentially life-threatening condition called non-alcoholic fatty liver disease. [More]

Liver fibrosis, which is the progressive formation of scar tissue in the liver, is a massive medical problem. An estimated ten percent of the population is affected by liver fibrosis or its corresponding later stage, liver cirrhosis. A variety of causes can lead to liver fibrosis, the most widely recognized ones being alcohol consumption and virus-induced chronic liver inflammation. [More]

In a new study published in Alimentary Pharmacology & Therapeutics, researchers at the University of Alberta's Faculty of Medicine & Dentistry have shown that a betaretrovirus which resembles a mouse mammary tumor virus infects patients with the rare liver disease, primary biliary cirrhosis (PBC). [More]

Researchers at Albert Einstein College of Medicine of Yeshiva University have found a possible clue to why older mothers face a higher risk for having babies born with conditions such as Down syndrome that are characterized by abnormal chromosome numbers. [More]

David Lim, MD, CM, of the University of Alberta has been named the winner of the 2015 Harry M. Vars Award by the American Society for Parenteral and Enteral Nutrition. The award is for his research on parenteral nutrition associated liver disease (PNALD) in infants, which was presented at A.S.P.E.N.'s Clinical Nutrition Week conference in Long Beach, California, February 14 to 17. [More]

Doctors believe that up to 30 percent of the U.S. population may have fat accumulation in the liver, known as non-alcoholic fatty liver disease (NAFLD), that can lead to a range of damaging health consequences. [More]

Cushing Disease, not to be confused with Cushing's Syndrome, is caused by a tumour in the pituitary gland in the brain. The tumour secrets increased amounts of the stress hormone adrenocorticotropin (ACTH) followed by cortisol release from the adrenal glands leading to rapid weight gain, elevated blood pressure and muscular weakness. [More]

Each year nearly 600,000 people--mostly children under age five and pregnant women in sub-Saharan Africa--die from malaria, caused by single-celled parasites that grow inside red blood cells. The most deadly malarial species--Plasmodium falciparum--has proven notoriously resistant to treatment efforts. [More]

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced top-line results from the 4 mg/kg cohort and additional results from the 2 mg/kg cohort in a completed clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR targeting microRNA-122 ("miR-122"), for the treatment of hepatitis C virus infection ("HCV"). [More]

Bariatric surgery--as a last resort when conservative interventions have failed--can improve liver disease and other obesity-related health problems in severely obese children and adolescents, according to a position paper in the Journal of Pediatric Gastroenterology and Nutrition, official journal of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition and the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. [More]

Marialena Mouzaki, MD, MSc, an assistant professor at University of Toronto and a staff gastroenterologist at Toronto's Hospital for Sick Children, has been named the Best International Abstract Awardee by the American Society for Parenteral and Enteral. The award is for her research on pediatric end-stage liver disease that she will present at A.S.P.E.N.'s Clinical Nutrition Week scientific conference in Long Beach, California, February 14 to 17. [More]

Between 5 and 8 million children in the United States have nonalcoholic fatty liver disease (NAFLD), yet most cases go undiagnosed. To help address this issue, researchers at UC San Diego School of Medicine have developed a new magnetic resonance imaging (MRI)-based technique to help clinicians and researchers better detect and evaluate NAFLD in children. [More]

Individuals previously infected with the hepatitis B virus (HBV) who receive chemotherapy or immunosuppressive treatment may be at risk of reactivating the disease according to a summary of report from the Emerging Trends Conference, "Reactivation of Hepatitis B," and published in Hepatology, a journal of the American Association for the Study of Liver Diseases. [More]

David Lim, MD, CM, of the University of Alberta has been named a Research Trainee Award recipient by the American Society for Parenteral and Enteral Nutrition. The award is for his research on parenteral nutrition associated liver disease (PNALD) in infants that he will present at A.S.P.E.N.'s Clinical Nutrition Week conference in Long Beach, California, February 14 to 17. [More]

News-Medical.net - An AZoNetwork Site
Owned and Operated by AZoM.com Limited Copyright 2000-2015

News-Medical.Net provides this medical information service in accordance
with these terms and conditions.
Please note that medical information found
on this website is designed to support, not to replace the relationship
between patient and physician/doctor and the medical advice they may provide.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Find out more here.